Dr. Lu named co-leader of EDT research program at IU Simon Comprehensive Cancer Center

Facebook
Twitter

Xiongbin Lu, Ph.D., has been named co-leader of the Experimental and Developmental Therapeutics (EDT) research program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Xiongbin Lu, Ph.D., has been named co-leader of the Experimental and Developmental Therapeutics (EDT) research program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Lu’s research interest spans across the field of cancer research, including human cancer genomics, targeted cancer therapy, and cancer immunotherapy with a focus on breast, ovarian, and colorectal cancers. He also has a long-standing interest in biomedical engineering, particularly nanoscale materials for cancer drug delivery.

He has made a number of seminal discoveries that promote translational development of human cancer research, including breast cancer targeted therapy and immunotherapy. His work has been published in many high-impact journals such as Nature, Nature Nanotechnology, and Cancer Cell.

Lu, a member of the cancer center, is the Vera Bradley Foundation Professor of Breast Cancer Innovation, professor of medical and molecular genetics, Strategic Research Initiative Distinguished Investigator, and co-leader of the TNBC Immunotherapy Initiative and Colorectal Cancer Working Group at IU School of Medicine.

Previously, Lu held faculty and leadership positions at Baylor College of Medicine, the Center for Colon Cancer Research at the University of South Carolina, and the University of Texas MD Anderson Cancer Center.

He earned his doctorate from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and he completed post-doctoral fellowships at the National Institutes of Health and Baylor College of Medicine.

He holds memberships in the American Association for Cancer Research, American Institute for Medical and Biological Engineering, and the Society of Chinese Bioscientists in America. He was inducted into the College of Fellows at the American Institute for Medical and Biological Engineering in 2019.

Lu serves as co-leader of the EDT research program with Mark Kelley, Ph.D. The program’s mission is to promote, develop, and exploit mechanism-based research for improved therapy of human cancer with a “bedside-to-bench-to-bedside approach.”

Normal
0

false
false
false

EN-US
X-NONE
X-NONE

MicrosoftInternetExplorer4

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:”Times New Roman”,serif;}